About
Selentus develops innovative haemostatic technologies for better surgical outcomes. Selentus is developing a pipeline of products based on its unique technology platform that offer high performance, low cost manufacture and avoid the use of blood-derived materials. Selentus' lead product, TenaTac®, was approved for sale in Europe in September 2019.
Technologies
Outlook
Varnish
Wix
Google Analytics
Mobile Friendly
Google Tag Manager
IoT
Android
Render
Avaya
Docker
Remote
Keywords
haemostats & tissue adhesion
medical equipment manufacturing
medical device development
surgical haemostat
cost-effective surgical tools
innovative haemostatic platform
blood-derived material avoidance
surgery
surgical wound management
product licensing
regulatory approval europe
patent portfolio
healthcare technology
bloodless haemostasis
b2b
healthcare
surgical bleeding complications
medical device pipeline
medical device innovation
surface modification
healthcare innovation
market expansion
wound therapy
wound sealing
haemostats
patented surface modification
surgical outcomes
surgical bleeding control
medical device pipeline development
low cost haemostats
Company Information
-
Employees 6
-
Founded 2016
Location
Grantham, England, United Kingdom, NG31 6SF
